Literature DB >> 15390330

Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation.

Uwe J F Tietge1, Oliver Selberg, Andreas Kreter, Matthias J Bahr, Matthias Pirlich, Wolfgang Burchert, Manfred J Müller, Michael P Manns, Klaus H W Böker.   

Abstract

With increasing long-term survival rates after orthotopic liver transplantation (OLT), metabolic alterations complicating the clinical course, such as diabetes mellitus (DM), become increasingly important. Liver cirrhosis is associated with severe alterations in glucose metabolism. However, it is currently unclear whether these changes are reversed by successful OLT. We therefore characterized glucose metabolism in patients with liver cirrhosis and normal fasting glucose levels before OLT (cir), in the clinically stable long-term course after OLT (OLT), and control subjects (con) using oral glucose tolerance tests (cir = 100, OLT = 62, con = 32), euglycemic-hyperinsulinemic clamps (cir = 10, OLT = 27, con = 14), and positron emission tomography (PET) scan analysis with 18F-fluorodeoxyglucose (FDG) as a tracer (cir = 7, OLT = 7, con = 5). Fasting insulin and C-peptide levels were significantly elevated in patients with liver cirrhosis compared with both control subjects (P <.001) and patients after OLT (P <.001). After OLT, insulin was normalized, whereas C-peptide remained elevated (P < 0.01). In the patients with liver cirrhosis, 27% had a normal glucose tolerance, 38% had an impaired glucose tolerance (IGT), and 35% were diabetic. After OLT, 34% had a normal glucose tolerance, 29% an IGT, and 37% were diabetic. Comparison of the same patients before and after OLT demonstrated that IGT or diabetes before OLT was the major risk factor for these conditions after OLT, which was independent of either immunosuppression (cyclosporine vs FK506) or low-dose prednisolone. Total glucose uptake was reduced in patients with liver cirrhosis to less than half the values in control subjects (21.2 +/- 2.8 vs 43.7 +/- 2.4 micromol/kg/minute, respectively, P <.001), whereas patients after OLT showed intermediate values (35.7 +/- 1.4 micromol/kg/minute, P < 0.05 vs con, P < 0.01 vs cir). This difference was caused by a reduction in nonoxidative glucose metabolism in patients with liver cirrhosis compared with control subjects (7.4 +/- 1.9 vs 28.7 +/- 1.8 micromol/kg/minute, respectively, P <.01) and patients after OLT (20.1 +/- 1.4 micromol/kg/minute, P < 0.05 vs con and OLT). In the PET study, skeletal muscle glucose uptake was significantly reduced in patients with liver cirrhosis compared with control subjects (3.5 +/- 0.4 vs 11.8 +/- 2.5 micromol/100g/minute, respectively, P <.05). After OLT, muscle glucose uptake improved compared with patients with liver cirrhosis (5.9 +/- 1.0 micromol/100g/minute, P <.05) but remained significantly lower than in control subjects (P <.05). In conclusion, these results demonstrate that preexisting IGT or diabetes are the major risk factors for IGT and diabetes after OLT. This finding was independent of the immunosuppressive medication. The peripheral insulin resistance in cirrhosis is characterized by a decrease in nonoxidative glucose disposal that is improved, but not normalized, after OLT.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15390330     DOI: 10.1002/lt.20147

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

Review 1.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  ESPEN guideline on clinical nutrition in liver disease.

Authors:  Mathias Plauth; William Bernal; Srinivasan Dasarathy; Manuela Merli; Lindsay D Plank; Tatjana Schütz; Stephan C Bischoff
Journal:  Clin Nutr       Date:  2019-01-16       Impact factor: 7.324

Review 3.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Animal PET for thioacetamide-induced rat cholangiocarcinoma: a novel and reliable platform.

Authors:  Chun-Nan Yeh; Kun-Ju Lin; Ing-Tsung Hsiao; Tzu-Chen Yen; Tsung-Wen Chen; Yi-Yin Jan; Yi-Hsiu Chung; Chung-Fu Lin; Miin-Fu Chen
Journal:  Mol Imaging Biol       Date:  2008-05-20       Impact factor: 3.488

Review 5.  Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test.

Authors:  Tsutomu Nishida
Journal:  J Endocr Soc       Date:  2017-05-23

Review 6.  Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives.

Authors:  Diego García-Compeán; Emanuela Orsi; Ramesh Kumar; Felix Gundling; Tsutomu Nishida; Jesús Zacarías Villarreal-Pérez; Ángel N Del Cueto-Aguilera; José A González-González; Giuseppe Pugliese
Journal:  World J Gastroenterol       Date:  2022-02-28       Impact factor: 5.742

Review 7.  Hepatogenous diabetes: Knowledge, evidence, and skepticism.

Authors:  Ramesh Kumar; Diego García-Compeán; Tanmoy Maji
Journal:  World J Hepatol       Date:  2022-07-27

8.  Potential usefulness of FDG PET/CT in patients with sepsis of unknown origin.

Authors:  Jing-Ren Tseng; Ke-Yuan Chen; Ming-Hsun Lee; Ching-Tai Huang; Ying-Hao Wen; Tzu-Chen Yen
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

Review 9.  Hepatogenous Diabetes: An Underestimated Problem of Liver Cirrhosis.

Authors:  Ramesh Kumar
Journal:  Indian J Endocrinol Metab       Date:  2018 Jul-Aug
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.